An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Melanoma

Next Previous
Trial Profile

An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Camrelizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 19 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 18 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top